PPARG and Hyperglycemia: Through the measurement of NF-κB transcriptional activity and FITC-Dextran permeability, Talé and colleagues evaluated the impact of the PPAR-γ agonist, pioglitazone on markers of the inflammatory response and permeability changes brought on by hyperglycemia [64].